BACKGROUND: Hypoxia inducible factor-1 has been identified as a potential target to overcome hypoxia-induced radioresistance The aim of the present study was to investigate whether selective HIF-1 inhibition via small interfering RNA (siRNA) targeting hypoxia-inducible factor 1α (HIF-1α) affects hypoxia-induced radioresistance in HT 1080 human fibrosarcoma cells. MATERIAL AND METHODS: HIF-1α expression in HT 1080 human fibrosarcoma cells in vitro was silenced using HIF-1α siRNA sequence primers. Quantitative real-time polymerase chain reaction assay was performed to quantify the mRNA expression of HIF-1α. HIF-1α protein levels were studied by Western blotting at 20% (air) or after 12 hours at 0.1% O2 (hypoxia). Cells were assayed for clonogenic survival after irradiation with 2, 5, or 10 Gy, under normoxic or hypoxic conditions in the presence of HIF-1α-targeted or control siRNA sequences. A modified oxygen enhancement ratio (OER´) was calculated as the ratio of the doses to achieve the same survival at 0.1% O(2) as at ambient oxygen tensions. OER´ was obtained at cell survival levels of 50%, 37%, and 10%. RESULTS: HIF-1α-targeted siRNA enhanced radiation treatment efficacy under severely hypoxic conditions compared to tumor cells treated with scrambled control siRNA. OER was reduced on all survival levels after treatment with HIF-1α-targeted siRNA, suggesting that inhibition of HIF-1 activation by using HIF-1α-targeted siRNA increases radiosensitivity of hypoxic tumor cells in vitro. CONCLUSION: Inhibition of HIF-1 activation by using HIF-1α-targeted siRNA clearly acts synergistically with radiotherapy and increase radiosensitivity of hypoxic cells in vitro.
BACKGROUND:Hypoxia inducible factor-1 has been identified as a potential target to overcome hypoxia-induced radioresistance The aim of the present study was to investigate whether selective HIF-1 inhibition via small interfering RNA (siRNA) targeting hypoxia-inducible factor 1α (HIF-1α) affects hypoxia-induced radioresistance in HT 1080 humanfibrosarcoma cells. MATERIAL AND METHODS:HIF-1α expression in HT 1080 humanfibrosarcoma cells in vitro was silenced using HIF-1α siRNA sequence primers. Quantitative real-time polymerase chain reaction assay was performed to quantify the mRNA expression of HIF-1α. HIF-1α protein levels were studied by Western blotting at 20% (air) or after 12 hours at 0.1% O2 (hypoxia). Cells were assayed for clonogenic survival after irradiation with 2, 5, or 10 Gy, under normoxic or hypoxic conditions in the presence of HIF-1α-targeted or control siRNA sequences. A modified oxygen enhancement ratio (OER´) was calculated as the ratio of the doses to achieve the same survival at 0.1% O(2) as at ambient oxygen tensions. OER´ was obtained at cell survival levels of 50%, 37%, and 10%. RESULTS:HIF-1α-targeted siRNA enhanced radiation treatment efficacy under severely hypoxic conditions compared to tumor cells treated with scrambled control siRNA. OER was reduced on all survival levels after treatment with HIF-1α-targeted siRNA, suggesting that inhibition of HIF-1 activation by using HIF-1α-targeted siRNA increases radiosensitivity of hypoxic tumor cells in vitro. CONCLUSION: Inhibition of HIF-1 activation by using HIF-1α-targeted siRNA clearly acts synergistically with radiotherapy and increase radiosensitivity of hypoxic cells in vitro.
Authors: P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe Journal: Science Date: 2001-04-05 Impact factor: 47.728
Authors: Maria Wolf; Franz Zehentmayr; Maximilian Niyazi; Ute Ganswindt; Wolfgang Haimerl; Michael Schmidt; Dieter Hölzel; Claus Belka Journal: Strahlenther Onkol Date: 2010-06-24 Impact factor: 3.621
Authors: Suzanne K Lau; Paul C Boutros; Melania Pintilie; Fiona H Blackhall; Chang-Qi Zhu; Dan Strumpf; Michael R Johnston; Gail Darling; Shaf Keshavjee; Thomas K Waddell; Ni Liu; Davina Lau; Linda Z Penn; Frances A Shepherd; Igor Jurisica; Sandy D Der; Ming-Sound Tsao Journal: J Clin Oncol Date: 2007-12-10 Impact factor: 44.544
Authors: E A Griffiths; S A Pritchard; H R Valentine; N Whitchelo; P W Bishop; M P Ebert; P M Price; I M Welch; C M L West Journal: Br J Cancer Date: 2006-12-19 Impact factor: 7.640
Authors: L Helbig; A Yaromina; S N Sriramareddy; S Böke; L Koi; H D Thames; M Baumann; D Zips Journal: Strahlenther Onkol Date: 2012-09-29 Impact factor: 3.621
Authors: A Yaromina; S Meyer; C Fabian; K Zaleska; U G A Sattler; L A Kunz-Schughart; W Mueller-Klieser; D Zips; M Baumann Journal: Strahlenther Onkol Date: 2012-02-16 Impact factor: 3.621